在接受陰莖海綿體注射血管活性藥物以治療陰莖勃起功能異常的150位病人的回顧性研究中，其中有32位病人經追蹤治療超過12個月。本篇研究是關於這32位病人治療分研報告。32位病人分成兩組，第一組18位病人接受前列腺素戊一型（prostaglandin, E1, PGE1）之治療，第二組14位病人接受罌粟鹼混合酚特氨（papaverine + phentolamine, PA+GE）。這些病人對此一治療方式皆感滿意，而繼續此一治療方式。在治療過程中，沒有特久性勃起（priapism）發生。6位病人(18.8%)有皮下血腫。有一位接受罌栗鹼混合酚特氨注射治療的病人發生陰結節，而另外一位接受同樣藥物的病人發生肝臟酵素升高現象。在32位病人中，有22位（68.8％）只需偶而注射藥物以幫助勃起，而剩下10位(31.2%)病人則是每次都必須藉助藥物來幫助勃起。這些結果經過統計分析（Student’s t-text以及chi-square analysis） 發現這兩組病人並沒有顯著差（P>0.05）。陰莖海綿體注射血管活性藥物是一有效且安全的陽萎的治療方式。

In retrospective study of 150 patients who had received intracavernous self-injection with vasoactive agents for the treatment of erectile dysfunction, 32 patients (21%), forllowed up for at least 12 months were evaluated in this study. Eighteen patients were administered prostaglandin E1 (Group I) and 14 patients a papaverine-regitine mixture (Group II). Most of the patients expressed satisfaction with the treatment. No priapism occurred in the course of therapy but six patients (18.8%) suffered from subcutaneous hematoma; there were two patients in group I and four patients in Group II. In Group II, one patient had a penile nodule after repeated injections and one patient had a penile nodule after repeated injections and one patient had a temporary increased in liver enzymes. Of the 32 patients, there were 22 (26.8%) who needed the therapy only intermittently while the other 10 patients (31.2%) usually remained dependent on the drugs in order to achieve satisfactory erection. There was no significant differences in effect between the two Groups.